as on November 11, 2025 at 2:29 am IST
Day's Low
Day's High
0.62%
Downside
1.75%
Upside
52 Week's Low
52 Week's High
40.71%
Downside
15.76%
Upside
Check Genmab A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$17.7B
EPS (TTM)
1.8812
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
1.08%
PE Ratio (TTM)
12.57
Industry PE ratio
19.200384615384614
PEG Ratio
1.0776
EBITDA
1.5B
Revenue (TTM)
3.8B
Profit Margin
41.17%
Return On Equity TTM
29.41%
Track how Genmab A/s P/E has moved over time to understand its valuation trends.
Genmab A/s in the last 5 years
Lowest (4.59x)
December 31, 2020
Today (12.57x)
November 10, 2025
Industry (19.20x)
November 10, 2025
Highest (64.13x)
September 30, 2021
Today’s Price to Earnings Ratio: 12.57x
Compare market cap, revenue, PE, and other key metrics of Genmab A/s with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $17.7B | -21.26% | 12.57 | 41.17% | |
| BUY | $40.5B | 443.24% | -16.34 | -264.83% | |
| BUY | $58.5B | 254.02% | 1428.06 | 1.36% | |
| BUY | $103.9B | 90.14% | 28.82 | 31.35% | |
| BUY | $69.1B | 17.58% | 15.77 | 32.13% |
The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Genmab A/s investment value today
Current value as on today
₹1,31,118
Returns
₹31,118
(+31.12%)
Returns from Genmab A/s Stock
₹25,953 (+25.95%)
Dollar Returns*
₹5,165 (+5.16%)
Based on 31 analysts
61.29%
Buy
29.03%
Hold
9.68%
Sell
Based on 31 analysts, 61.29% of analysts recommend a 'BUY' rating for Genmab A/s. Average target price of $37.1
Get share price movements and forecasts by analysts on Genmab A/s.
What analysts predicted
21.64%UPSIDE
Target Price
$37.1
Current Price
$29.07
Analyzed by
31 Analysts
Target
$37.10
Genmab A/s target price $37.1, a slight upside of 21.64% compared to current price of $29.07. According to 31 analysts rating.
Investment in Genmab A/s Shares on INDmoney has grown by 295.00% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:295.00% versus previous 30 day period
Search interest for Genmab A/s Stock has increased by 36% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:36% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 06 November
Thu, 11:05 PM
-Genmab A/S reports Q3 earnings: sales up 25% to $1,022 million, net income rises to $401 million.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
![]()
Netprofit is up for the last 2 quarters, 195.0M → 2.12B (in $), with an average increase of 90.8% per quarter
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 715.0M → 5.86B (in $), with an average increase of 87.8% per quarter
Price Rise
![]()
In the last 3 months, GMAB stock has moved up by 33.7%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 158.0% return, outperforming this stock by 133.8%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 879.3% return, outperforming this stock by 913.4%
| Organisation | Genmab A/s |
| Headquarters | Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 |
| Industry | Health Technology |
| CEO | Dr. Jan G.J. van de Winkel Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director |
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
Mr. Anthony Pagano CPA | Executive VP & CFO |
Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer |
Mr. Christopher Cozic | Executive VP & Chief People Officer |
Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director |
Genmab A/s share price today is $29.07 as on at the close of the market. Genmab A/s share today touched a day high of $29.58 and a low of $28.89.
Genmab A/s share touched a 52 week high of $33.65 on and a 52 week low of $17.24 on . Genmab A/s stock price today i.e. is closed at $29.07,which is 13.61% down from its 52 week high and 68.67% up from its 52 week low.
Genmab A/s market capitalisation is $0.02T as on .
Indian investors can start investing in Genmab A/s (GMAB) shares with as little as ₹88.675 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.75 in Genmab A/s stock (as per the Rupee-Dollar exchange rate as on ).
Based on Genmab A/s share’s latest price of $29.07 as on November 11, 2025 at 2:29 am IST, you will get 0.3440 shares of Genmab A/s. Learn more about
fractional shares .
Genmab A/s stock has given -21.26% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?